Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

ICPT

Intercept Pharmaceuticals (ICPT)

Intercept Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ICPT
FechaHoraFuenteTítuloSímboloCompañía
09/05/202407:00GlobeNewswire Inc.Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 ConferenceNASDAQ:ICPTIntercept Pharmaceuticals Inc
29/02/202407:30GlobeNewswire Inc.Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBCNASDAQ:ICPTIntercept Pharmaceuticals Inc
20/11/202311:09Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:ICPTIntercept Pharmaceuticals Inc
14/11/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ICPTIntercept Pharmaceuticals Inc
13/11/202313:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ICPTIntercept Pharmaceuticals Inc
13/11/202307:00GlobeNewswire Inc.Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023NASDAQ:ICPTIntercept Pharmaceuticals Inc
10/11/202307:00GlobeNewswire Inc.Intercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023NASDAQ:ICPTIntercept Pharmaceuticals Inc
08/11/202315:44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ICPTIntercept Pharmaceuticals Inc
08/11/202315:28Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:ICPTIntercept Pharmaceuticals Inc
08/11/202315:21Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ICPTIntercept Pharmaceuticals Inc
08/11/202308:21Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:ICPTIntercept Pharmaceuticals Inc
08/11/202308:13GlobeNewswire Inc.Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.NASDAQ:ICPTIntercept Pharmaceuticals Inc
08/11/202306:50Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:ICPTIntercept Pharmaceuticals Inc
08/11/202305:04Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:ICPTIntercept Pharmaceuticals Inc
06/11/202316:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ICPTIntercept Pharmaceuticals Inc
11/10/202315:34Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:ICPTIntercept Pharmaceuticals Inc
11/10/202315:16Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:ICPTIntercept Pharmaceuticals Inc
10/10/202310:10Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:ICPTIntercept Pharmaceuticals Inc
28/09/202316:17Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:ICPTIntercept Pharmaceuticals Inc
26/09/202307:00GlobeNewswire Inc.Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver DiseasesNASDAQ:ICPTIntercept Pharmaceuticals Inc
05/09/202307:30GlobeNewswire Inc.Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor ConferencesNASDAQ:ICPTIntercept Pharmaceuticals Inc
02/08/202306:00GlobeNewswire Inc.Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:ICPTIntercept Pharmaceuticals Inc
26/07/202307:00GlobeNewswire Inc.Intercept to Announce Second Quarter 2023 Financial Results on August 2, 2023NASDAQ:ICPTIntercept Pharmaceuticals Inc
10/07/202309:41Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ICPTIntercept Pharmaceuticals Inc
23/06/202305:36Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ICPTIntercept Pharmaceuticals Inc
23/06/202305:30GlobeNewswire Inc.Intercept Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating ExpensesNASDAQ:ICPTIntercept Pharmaceuticals Inc
23/06/202301:45GlobeNewswire Inc.Intercept Presents New Data Showing Significant Impact of OCA-bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver DamageNASDAQ:ICPTIntercept Pharmaceuticals Inc
22/06/202317:36Dow Jones NewsIntercept Pharma Discontinues NASH-Related Investment, Will Focus on Liver DiseasesNASDAQ:ICPTIntercept Pharmaceuticals Inc
22/06/202316:45GlobeNewswire Inc.Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASHNASDAQ:ICPTIntercept Pharmaceuticals Inc
16/06/202315:02Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ICPTIntercept Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ICPT

Su Consulta Reciente

Delayed Upgrade Clock